Table 3.
Clinical thrombophilic risk factors in association with pre-transplant PVT cases
| With pre-transplant PVT (n = 62) | Without pre-transplant PVT (n = 318) | Significance | |
|---|---|---|---|
| Child/adult recipient |
2/60 |
48/270 |
p = 0.011 |
| Male/female recipient |
44/18 |
210/108 |
p = 0.451 |
| Associated tumor (Yes/No) |
15/32 |
63/133 |
p = 0.951 |
| Diabetes mellitus and/or high lipid (Yes/No) |
24/25 |
68/135 |
p = 0.043 |
| Inflammatory disease (Yes/No) |
0/39 |
0/183 |
p = N |
| Smoking (Yes/No) |
20/26 |
111/92 |
p = 0.169 |
| Inmobility (Yes/No) |
3/36 |
9/166 |
p = 0.531 |
| Surgery Intervention (Yes/No) |
24/23 |
104/103 |
p = 0.919 |
| Obesity (Yes/No) |
5/37 |
4/178 |
p = 0.004 |
| Nephrotic syndrome (Yes/No) |
0/39 |
14/163 |
p = 0.069 |
| Myeloproliferative syndrome (Yes/No) |
2/39 |
0/185 |
p = 0.003 |
| Trauma (Yes/No) |
3/37 |
10/171 |
p = 0.631 |
| Cause of liver transplantation |
|
|
p = 0.135 |
| BHV |
2 |
16 |
|
| CHV |
12 |
61 |
|
| Ethanol |
14 |
48 |
|
| Autoimmune |
3 |
5 |
|
| Toxicity |
1 |
7 |
|
| Tumor |
7 |
22 |
|
| Cryptogenetic |
1 |
14 |
|
| Vascular |
2 |
0 |
|
| Infrequent (deficit alpha1 antitrypsin) |
3 |
23 |
|
| Biliary atresia |
2 |
22 |
|
| BHV and CHV |
10 |
42 |
|
| BHV and CHV and Tumor | 5 | 58 |
HCV, hepatitis C virus; HBV, hepatitis B virus; PVT, portal vein thrombosis. Data on height was available in 224 of 380 recipients. The body mass index (BMI) was calculated as weight in kilograms/height in meters squared. Obesity was considered when BMI > 30 kg/m2. Missing Values: associated tumor (138); DM and/or High lipid (128); Inflammatory disease (158); Smoking (131); Inmobility (166); Surgery Intervention (126); Nephrotic Syndrome (164); Myeloproliferative Syndrome (159); Trauma (159).